Abstract
Psoriasis is a chronic inflammatory skin disorder resulting from a complex network of cytokines and chemokines produced by various immune cell types and tissue cells. Emerging evidence suggests a central role of IL-17 and IL-23/T17 axis in the pathogenesis of psoriasis, giving a rationale for using IL-17-blocking agents as therapeutics. Three agents targeting IL-17 signaling are being studied in Phase III clinical trials: secukinumab and ixekizumab (IL-17 neutralizing agents), and brodalumab (IL-17 receptor antagonist). Preliminary results are highly promising for all anti-IL17 agents, creating fair expectations on this class of agents as the new effective therapeutic approach for the treatment of psoriasis.
| Lingua originale | Inglese |
|---|---|
| pagine (da-a) | 9-20 |
| Numero di pagine | 12 |
| Rivista | Actas Dermo-Sifiliograficas |
| Volume | 105 |
| Numero di pubblicazione | 1 |
| DOI | |
| Stato di pubblicazione | Pubblicato - 2014 |
OSS delle Nazioni Unite
Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile
-
SDG 3 Salute e benessere
All Science Journal Classification (ASJC) codes
- Anatomia Patologica e Medicina Forense
- Istologia
- Dermatologia
Keywords
- Arthritis
- Atherosclerosis
- Brodalumab
- IL-17
- Ixekizumab
- Obesity
- Psoriasis
- Secukinumab
Fingerprint
Entra nei temi di ricerca di 'Pathogenic role of IL-17 in psoriasis and psoriatic arthritis'. Insieme formano una fingerprint unica.Cita questo
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver